ClinicalTrials.gg
Status unknownNCT04528147Updated Aug 27, 2020

Yi Jin Jing Tiger Roaring Speech Rehabilitation With Real-Time Feedback Technique for PD

An interventional study of Yi Jin Jing Tiger Roaring Speech Rehabilitation and Conventional Speech Rehabilitation in Speech Disorders and Parkinson Disease, sponsored by Ruijin Hospital. Status unknown at 1 site in China. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-27.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Speech disorders affect more than 90% of patients with Parkinson's disease (PD). Neither of conventional drugs nor surgery can effectively improve speech function. Western speech rehabilitation is effective for speech disorders, but the domestic use of those methods used is limited. Our preliminary results revealed that traditional Chinese Yi jin jing tiger roaring speech rehabilitation is effectively in the treatment of speech disorders in PD, however, high-quality clinical evidence is still scarce. In order to solve this problem, we will conduct a prospective cohort study to explore the effects of Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique on speech disorders in PD patients. This study will help to establish a set of Chinese Medicine treatment and objective evaluation methods for PD speech disorders.

02

Conditions studied

  • Speech Disorders
  • Parkinson Disease
03

In context

Speech Disorders

77 studies on the registry are indexed under Speech Disorders; 20 are open to participants now.

This study's planned enrollment of 20 is below the median of 38 across 54 interventional studies indexed under Speech Disorders.

Browse Speech Disorders studies →

Lead sponsor

Ruijin Hospital is the lead sponsor of 679 studies on the registry; 387 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with idiopathic Parkinson's disease
  • Native language is Chinese
  • VHI-10 score more than 10

Exclusion criteria

Exclusion Criteria:

  • Previous or concurrent medical history affecting swallowing function (laryngeal diseases such as vocal nodules, gastroesophageal reflux, and laryngeal cancer).
  • History of serious psychosis
  • Diagnosed by the investigators that patients with severe cardiac, liver and kidney diseases, or other serious health conditions
  • Dementia (A (MMSE) score of \< 24), inability to comprehend the experimental protocol or voluntarily provide
  • Lack of cooperation
  • Additional reasons for exclusion at the discretion of the clinical investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Yi Jin Jing Tiger Roaring Speech Rehabilitation

    Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.

    Behavioral: Yi Jin Jing Tiger Roaring Speech Rehabilitation

  • Experimental
    Conventional Speech Rehabilitation

    Patients will receive speech rehabilitation recommended by The Parkinson's Foundation. Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.

    Behavioral: Conventional Speech Rehabilitation

Interventions

  • BehavioralYi Jin Jing Tiger Roaring Speech Rehabilitation

    A traditional Chinese medicine treatment

  • BehavioralConventional Speech Rehabilitation

    A active speech rehabilitation method recommended by the Parkinson's Foundation of America

06

What researchers measure

Primary outcomes

  1. Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states

    The Voice Handicap Index is a self-administered instrument, comprising 30 items on voice-related dysfunction. VHI has a range of 0 (normal voice function) to 120 (severe voice dysfunction).

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

Secondary outcomes

  1. Differences in voice parameters between treatment conditions in the on- and off- medication states

    Voice recording at a sampling rate of 44.1 kHz using 16-bit quantification will be conducted in a sound-treated room using a microphone and a digital voice recorder with a mouth-to-microphone distance of 15 cm. The recorded voices will then be used for a composit acoustic analysis.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  2. Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.

    Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  3. Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.

    Burg Balance Scale measures patients' static and dynamic balance abilities. BBS score has a range of 0 (severe balance problems) to 56 (no balance problems).

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  4. Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.

    The Water Swallow Test is frequently used in clinical practice as a functional assessment to detect dysphagia, with stage 1 indicating severe dysphagia and stage 6 indicating normal swallowing function.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  5. Differences in Beck Depression Inventory (BDI) scores between Treatment conditions.

    Beck Depression Inventory is a self-administered Instrument, contains 21 self-report items. The items are scored as 0, 1, 2, or 3. The score range is 0 (no depression) to 63 (severe depression).

    Time frame: Baseline, 4 weeks

  6. Differences in Beck Anxiety Inventory (BAI) scores between treatment conditions.

    The BAI is a rating scale used to evaluate the severity of anxiety symptoms. It contains 21 self-report items. The items are scored as 0, 1, 2, or 3. The score range is 0-63. A total score of 0-7 is considered minimal range, 8-15 is mild, 16-25 is moderate, and 26-63 is severe.

    Time frame: Baseline, 4 weeks

  7. Differences in 8-item Parkinson's Disease Questionnaire (PDQ-8) scores between treatment conditions.

    8-item Parkinson's Disease Questionnaire is a 8-item health-related quality of life instrument for subjects with Parkinson's Disease, which has a score range of 0 (good life quality) to 32 (very bad life quality).

    Time frame: Baseline, 4 weeks

07

Study locations

1 site
  • Functional neurosurgery of Shanghai jiaotong university affiliated Ruijin hospital
    Shanghai, Shanghai 200025, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04528147
Lead sponsor
Ruijin Hospital
Responsible party
Bomin Sun (Chief physician, Ruijin Hospital) — Principal investigator
First posted
Aug 27, 2020
Start date
Oct 1, 2020 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Aug 27, 2020

Study contacts

Dianyou Li, MD, PhD
Contact
ldy11483@rjh.com.cn
+8613817864569

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion